Analysis of the mechanism of HCMV cytoplasmic envelopment
HCMV胞质包膜机制分析
基本信息
- 批准号:10659275
- 负责人:
- 金额:$ 48.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-07-17 至 2027-12-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAntiviral AgentsBiological AssayCapsidCell NucleusClinicalComplexCytomegalovirusCytoplasmDNA PackagingDNA biosynthesisDataDiseaseEarly EndosomeEndosomesEventFluorescenceGeographic LocationsHumanImageImmunocompromised HostIndividualInfectionInterventionInvestigationKnowledgeLearningLife Cycle StagesLinkMass Spectrum AnalysisMediatingMembraneMolecularMolecular MotorsNeckNewborn InfantOrganellesPredispositionPregnant WomenProcessProtein AnalysisProteinsPublishingRoleSiteStructural ModelsTherapeuticTherapeutic immunosuppressionViralViral ProteinsVirionVirusVirus AssemblyVirus ReplicationWorkaging populationantiviral drug developmentclinically relevantexperimental studyimprovedinsightinterestnovelnovel therapeutic interventionresistance mutationscreeningsocioeconomicstargeted treatmenttraffickingviral fitness
项目摘要
Although largely asymptomatic, human cytomegalovirus (HCMV) can cause severe and even fatal disease in a subset of susceptible individuals. While great progress has been made in understanding essential stages of HCMV replication, a detailed description of many of these processes is lacking. Of particular interest in this proposal is the maturation of HCMV virions, namely tegument acquisition and cytoplasmic envelopment. To provide a molecular description of these events, it is important to identify the factors involved, both viral and cellular. This proposal will focus on two viral proteins, UL88 and UL71. We have previously published a role for UL88 in packaging a subset of tegument proteins into the virion tegument layer and the absence of UL88 decreases viral fitness. Previous work has identified UL71 as an envelopment factor that potentially mediates membrane scission, as viruses lacking UL71 are trapped at various stages of budding. The experiments in this proposal will seek to elucidate the molecular details of how UL88 and UL71 drive tegument acquisition and envelopment, respectively. This includes a detailed analysis of functional regions on each protein as well as an investigation into additional factors that potentially contribute to each process. We will investigate the role of EEA1+ endosomes in tegument acquisition and for the membrane scission factor DNM1 in cytoplasmic envelopment. This proposal will utilize a novel fluorescence-based envelopment to identify additional cellular proteins that participate in envelopment. Taken together, these studies will further our understanding of the molecular events that drive the late stages of HCMV maturation and identify novel ways in which HCMV assembly can be targeted as a potential intervention.
尽管在很大程度上是无症状的,但人类巨细胞病毒(HCMV)可能会在易感人群的一部分中引起严重甚至致命的疾病。尽管在理解HCMV复制的基本阶段方面取得了巨大进展,但缺乏对许多这些过程的详细描述。在这一建议中特别感兴趣的是HCMV病毒体的成熟,即收购和细胞质包膜。为了提供这些事件的分子描述,重要的是要确定涉及的因素,包括病毒和细胞。该提案将重点介绍两种病毒蛋白UL88和UL71。我们以前曾在将Tegument蛋白的子集包装到病毒座层中,并发表了UL88的作用,并且不存在UL88会降低病毒适应性。先前的工作已经将UL71确定为可能介导膜分裂的包络因子,因为缺乏UL71的病毒被困在各个萌芽阶段。该提案中的实验将旨在阐明UL88和UL71分别驱动tegument的获取和信封的分子细节。这包括对每种蛋白质功能区域的详细分析,以及对潜在有助于每个过程的其他因素的研究。我们将研究EEA1+内体在TEGUMEMENT获得的作用以及在细胞质包膜中膜分裂因子DNM1的作用。该建议将利用一种新型的基于荧光的信封来识别参与包膜的其他细胞蛋白。综上所述,这些研究将进一步理解驱动HCMV成熟后期阶段的分子事件,并确定可以将HCMV组装作为潜在干预措施的新颖方式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher C Norbury其他文献
Christopher C Norbury的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher C Norbury', 18)}}的其他基金
How does Cytomegalovirus use interferon lambda for optimal spread
巨细胞病毒如何利用 lambda 干扰素实现最佳传播
- 批准号:
10552002 - 财政年份:2022
- 资助金额:
$ 48.76万 - 项目类别:
The effect of local virus infection upon cutaneous wound healing: the impact of virus-induced Type III IFNs
局部病毒感染对皮肤伤口愈合的影响:病毒诱导的III型干扰素的影响
- 批准号:
10433972 - 财政年份:2021
- 资助金额:
$ 48.76万 - 项目类别:
The effect of local virus infection upon cutaneous wound healing: the impact of virus-induced Type III IFNs
局部病毒感染对皮肤伤口愈合的影响:病毒诱导的III型干扰素的影响
- 批准号:
10217681 - 财政年份:2021
- 资助金额:
$ 48.76万 - 项目类别:
Interferon-independent STAT1-mediated protective antiviral immunity
不依赖干扰素的STAT1介导的保护性抗病毒免疫
- 批准号:
9378819 - 财政年份:2017
- 资助金额:
$ 48.76万 - 项目类别:
Processing & Presentation of Ectromelia Virus to CD4+ T Lymphocytes - Asso Projec
加工
- 批准号:
7982871 - 财政年份:2009
- 资助金额:
$ 48.76万 - 项目类别:
相似国自然基金
核苷类抗病毒药物嵌合型核酸纳米载体的构筑及其抗病毒性能研究
- 批准号:52303174
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向病毒核衣壳蛋白质相分离的抗病毒药物发现及机制研究
- 批准号:82302491
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
水环境中抗病毒药物及其转化副产物的识别及生态毒性效应研究
- 批准号:52300245
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
猴痘病毒入侵融合复合物、DNA聚合酶复合物的结构解析以及抗病毒药物的开发
- 批准号:82241081
- 批准年份:2022
- 资助金额:65.00 万元
- 项目类别:专项项目
CCHFV的致病机理及抗病毒药物研究
- 批准号:U22A20336
- 批准年份:2022
- 资助金额:255.00 万元
- 项目类别:联合基金项目
相似海外基金
Development of antibody drug conjugates as pan-filo antivirals
开发作为泛型抗病毒药物的抗体药物偶联物
- 批准号:
10759731 - 财政年份:2023
- 资助金额:
$ 48.76万 - 项目类别:
High throughput screening and drug discovery for antagonists of the Ebola VP40 protein assembly
埃博拉 VP40 蛋白组装拮抗剂的高通量筛选和药物发现
- 批准号:
10760573 - 财政年份:2023
- 资助金额:
$ 48.76万 - 项目类别:
Intracellular functions and mechanisms of alphavirus ion channel 6K
甲病毒离子通道6K的细胞内功能和机制
- 批准号:
10727819 - 财政年份:2023
- 资助金额:
$ 48.76万 - 项目类别:
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus
IN-002 的 GMP 生产和 IND 备案,这是一种针对呼吸道合胞病毒的有效吸入粘液捕获抗体疗法
- 批准号:
10761398 - 财政年份:2023
- 资助金额:
$ 48.76万 - 项目类别:
Development of a first-in-class antiviral to address CMV drug resistance in immunocompromised patients
开发一流的抗病毒药物来解决免疫功能低下患者的 CMV 耐药性问题
- 批准号:
10766598 - 财政年份:2023
- 资助金额:
$ 48.76万 - 项目类别: